Ani Pharmaceuticals (ANIP) Operating Income Growth (3y) (2015 - 2026)
Ani Pharmaceuticals (ANIP) Operating Income Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn | 273.62% |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn | 3.84% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | -59.82% |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn | 4.63% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn | -30.05% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | 54.58% |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn | 40.17% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 57.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.81% |
| Dec 31, 2025 | 167.32% |
| Sep 30, 2025 | 109.96% |
| Jun 30, 2025 | 45.43% |
| Mar 31, 2025 | 49.85% |
| Dec 31, 2024 | 43.07% |
| Sep 30, 2024 | -79.26% |
| Jun 30, 2024 | 32.62% |
| Mar 31, 2024 | 88.24% |
| Dec 31, 2023 | 172.88% |
| Sep 30, 2023 | 85.72% |
| Jun 30, 2023 | 45.76% |
| Mar 31, 2023 | 48.30% |
| Dec 31, 2022 | 33.69% |
| Sep 30, 2022 | -38.93% |
| Jun 30, 2022 | -50.22% |
| Mar 31, 2022 | -85.28% |
| Dec 31, 2021 | -59.70% |
| Sep 30, 2021 | -32.99% |
| Jun 30, 2021 | -60.59% |